Gvoke™ (glucagon injection)

Gvoke HypoPen 2-Pack™ and Gvoke PFS 2-Pack™

For the treatment of severe hypoglycemia in adults and pediatric patients with diabetes ages 2 and above[1]

- Liquid stable glucagon administered through subcutaneous injection[1]
- Instant confirmation of full-dose delivery[2,3]

Gvoke HypoPen™ or Gvoke™ Pre-Filled Syringe (PFS) is available in 2 dosing options[1]:

- 0.5 mg/0.1 mL for patients <12 years
- 1.0 mg/0.2 mL for patients ≥12 years or who weigh ≥100 lbs

Gvoke HypoPen and Gvoke PFS are not AB rated.[4] Therefore, substitution is not allowed.

Name	Dose	Unit of Measure	NDC	Administration	Units per Package Size	WAC Price
Gvoke HypoPen 2-Pack	0.5 mg/0.1 mL (pediatric)	mL	72065-0120-12	Autoinjector	2	$561.60
Gvoke HypoPen 2-Pack	1.0 mg/0.2 mL (adult)	mL	72065-0121-12	Autoinjector	2	$561.60
Gvoke PFS 2-Pack	0.5 mg/0.1 mL (pediatric)	mL	72065-0130-12	Pre-Filled Syringe	2	$561.60
Gvoke PFS 2-Pack	1.0 mg/0.2 mL (adult)	mL	72065-0131-12	Pre-Filled Syringe	2	$561.60

covermymeds®

CoverMyMeds — When Prior Authorization (PA) Is Required

CoverMyMeds automates the prior authorization process, making it a faster and easier way to review, complete, and track PA requests. The electronic prior authorization solution is HIPAA compliant and available for all plans and all medications at no cost to pharmacists and their staff.

Please contact your wholesale distribution center if Gvoke HypoPen and Gvoke PFS are not available in your system.

xeris PHARMACEUTICALS

See Important Safety Information on last page.

Reading a Gvoke™ Prescription



For a limited time, eligible commercially insured patients may pay as little as $0.*

Click here to download the Gvoke Copay Card.

*Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, TRICARE, or other federal or state health programs (such as medical assistance programs).

INDICATION AND IMPORTANT SAFETY INFORMATION

GVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.

IMPORTANT SAFETY INFORMATION

Contraindications

GVOKE is contraindicated in patients with pheochromocytoma, insulinoma, and known hypersensitivity to glucagon or to any of the excipients in GVOKE. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.

Warnings and Precautions

GVOKE is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor. If the patient develops a dramatic increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.

In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, GVOKE administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. GVOKE is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of GVOKE, give glucose orally or intravenously.

Allergic reactions have been reported with glucagon. These include generalized rash, and in some cases, anaphylactic shock with breathing difficulties and hypotension. GVOKE is contraindicated in patients with a prior hypersensitivity reaction.

GVOKE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia, may not have adequate levels of hepatic glycogen for GVOKE administration to be effective. Patients with these conditions should be treated with glucose.

Necrolytic migratory erythema (NME), a skin rash commonly associated with glucagonomas has been reported postmarketing following continuous glucagon infusion and resolved with discontinuation of the glucagon. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks. Glucagon administered to patients with glucagonoma may cause secondary hypoglycemia.

Adverse Reactions

Most common (≥5%) adverse reactions associated with GVOKE are nausea, vomiting, injection site edema (raised 1 mm or greater), and hypoglycemia.

Drug Interactions

Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE. In patients taking indomethacin, GVOKE may lose its ability to raise blood glucose or may even produce hypoglycemia. GVOKE may increase the anticoagulant effect of warfarin.

Please click here for full Prescribing Information for Gvoke Hypopen and Gvoke PFS.

References:
1. Gvoke [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc; 2019. **2.** Gvoke HypoPen [instructions for use]. Chicago, IL: Xeris Pharmaceuticals, Inc; 2019. **3.** Gvoke PFS [instructions for use]. Chicago, IL: Xeris Pharmaceuticals, Inc; 2019. **4.** US Food and Drug Administration. Prescription and over-the-counter drug product list. 39th ed. Cumulative supplement number 09: September 2019. Additions/deletions for prescription drug product list. https://www.fda.gov/media/131880/download. Accessed January 24, 2020.

xeris PHARMACEUTICALS